Korean J Urol.  2015 Dec;56(12):847-848. 10.4111/kju.2015.56.12.847.

The authors reply: Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia

• Kabir A
• Cyrus A

• KMID: 2359879
• DOI: http://doi.org/10.4111/kju.2015.56.12.847

Abstract

No abstract available.

MeSH Terms

Humans
*Metabolic Syndrome X
*Prostatic Hyperplasia

Reference

1. Cyrus A, Kabir A, Goodarzi D, Talaei A, Moradi A, Rafiee M, et al. Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia. Korean J Urol. 2014; 55:814–820.

2. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015; 67:1099–1109.

3. Anwarul Islam AK, Kashem MA, Shameem IA, Kibria SA. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: a comparative study. Bangladesh Med Res Counc Bull. 2005; 31:54–61.

4. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology. 2001; 58:203–209.

5. Baldwin KC, Ginsberg PC, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urol Int. 2001; 66:84–88.